BGM Group (BGM) Price/OCF Ratio: History & Chart

BGM Group Ltd.(BGM)

Drug Manufacturers - Specialty & Generic · Chengdu, SIC

$9.35+0.01 (+0.11%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About BGM Group Ltd.

Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.

Chengdu, SIC

298 employees

www.bgmgroupltd.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Chen Xin

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
BGM Group Ltd. (BGM)	$118.63M	N/A	N/A	N/A	N/A
Caribou Biosciences, Inc. (CRBU)vs ›	$118.02M	N/A	N/A	N/A	N/A
Foghorn Therapeutics Inc. (FHTX)vs ›	$117.43M	N/A	1.65	1.65	1.65
Aardvark Therapeutics, Inc. Common Stock (AARD)vs ›	$114.24M	N/A	N/A	N/A	N/A
Coya Therapeutics, Inc. (COYA)vs ›	$113.77M	N/A	N/A	N/A	N/A
enGene Holdings Inc. (ENGN)vs ›	$125.27M	N/A	N/A	N/A	N/A
Black Diamond Therapeutics, Inc. (BDTX)vs ›	$111.17M	N/A	8.98	8.98	8.98
Apyx Medical Corporation (APYX)vs ›	$109.49M	N/A	N/A	N/A	N/A
Cibus, Inc. (CBUS)vs ›	$128.24M	N/A	N/A	N/A	N/A
Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs ›	$108.39M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

BGM Group Ltd. (BGM)

$118.63M

N/A

Caribou Biosciences, Inc. (CRBU)vs ›

$118.02M

N/A

Foghorn Therapeutics Inc. (FHTX)vs ›

$117.43M

N/A

1.65

Aardvark Therapeutics, Inc. Common Stock (AARD)vs ›

$114.24M

N/A

Coya Therapeutics, Inc. (COYA)vs ›

$113.77M

N/A

enGene Holdings Inc. (ENGN)vs ›

$125.27M

N/A

Black Diamond Therapeutics, Inc. (BDTX)vs ›

$111.17M

N/A

8.98

Apyx Medical Corporation (APYX)vs ›

$109.49M

N/A

Cibus, Inc. (CBUS)vs ›

$128.24M

N/A

Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs ›

$108.39M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

BGM Price/OCF Ratio Metrics

BGM Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics